BUSINESS OVERVIEW

• Headquartered in the UK with fully equiped research & development laboratory on a single site.
• Proprietary system encompasses universal bacteria and candida capture, detection, digital Gram identification with enumeration and growth monitoring capabilities directly from whole blood.
• Designed as an ultra-purified, cost-effective alternative to blood culture to reduce time-to-result of existing molecular BCID, rapid AST and NGS systems.
• The fully automated system can be configured to meet the workflow requirements of laboratories and downstream molecular, AST, NGS analysers.
• Data presented in peer reviewed journals and international congress demonstrate time-to-result in 6-12hrs not days often experienced using the current standard of care.   
• Reduced time to diagnosis allows for faster, more precise targeting of antibiotics for sepsis patients, rapid determination of antimicrobial resistance (AMR) and healthcare system cost savings.
• Comprehensive IP and patented technology available.
• The Company operates to high standards of Quality Management and is certificated against ISO 13485:2016 including GLP & GMP. 
• Highly specialised and talented R&D team.
• Well maintained laboratory equipment.
• Leasehold premises.

IMPORTANT

This briefing sheet contains information supplied by company personnel. LSH provides no warranties or indemnities in respect of such information. All interested parties must rely on their own investigations when reviewing this opportunity.